Mefloquine during the study. Mefloquine was the first Public-Private Venture (PPV) between the US Department of Defense and a pharmaceutical company. WRAIR transferred all its phase I and phase II clinical trial data to Hoffman LaRoche and Smith Kline. FDA approval as a treatment for malaria was swift. Most notably, phase III safety and tolerability trials were skipped. The drug was first approved and sold on a commercial basis in Switzerland in 1985. However, mefloquine was not approved by the FDA for prophylactic use until 1989. This approval was based primarily on compliance, while safety and tolerability were overlooked. Because of
International Association for the Treatment of Sexual Offenders the context of their family, school, and other social systems in order to fully understand and decide the treatment and care for the juvenile. Another important element to keep in mind when choosing a treatment is to base it on a developmental perspective, which means it is sensitive to developmental change. This is necessary because during adolescence the brain is not fully developmental and is subjected to change. During assessment and treatment focus not only on the risks of the youths but also their strengths. Keep in mind that sexual interests of youth do change over adolescence and sexual orientation